17754 Treatment success in mild psoriasis patients with fixed-combination calcipotriene and betamethasone dipropionate foam: Results from the PSO-FAST trial

Document Type

Conference Proceeding

Publication Date

12-2020

Publication Title

J Am Acad Dermatol

Abstract

Background: Numerous topical and systemic therapies are available for the treatment of cutaneous psoriasis; very few have been demonstrated effective for mild psoriasis. We evaluated efficacy in a mild patient cohort with once-daily application of Cal/BD foam for 4 weeks in a post hoc analysis. Methods: Adults with mild-severe plaque psoriasis (IGA ≥2;, BSA 2%-30%) were randomized 3:1 to Cal/BD foam (n = 323) or vehicle (n = 103) once daily for up to 4 weeks (Leonardi et al, J Drugs Dermatol 2015;14:1468-77). Patient characteristics and IGA ‘treatment success’ was determined for patients with mild psoriasis (IGA = 2 according to 5-point IGA). ‘Treatment success’ for mild patients required a 2-grade IGA improvement with a rating of ‘clear’ (IGA = 0) at week 4 (Mantel-Haenszel). Results: At baseline, 65/426 patients in PSO-FAST had mild psoriasis; mean duration was 14 years, BSA% = 4.8 and mPASI = 4.7. After 4 weeks, significantly more patients with mild psoriasis achieved treatment success with Cal/BD foam than foam vehicle with 30.6% versus 0.0% [P =.019] being clear of visible psoriasis lesions. Similarly, reductions in mPASI from baseline were −35.5, −55.3, and −71.9, respectively for Cal/BD foam at week 1, 2, and 4 vs vehicle −15.2, −25.0, and −27.7. PASI-75 at week 4 was 49.0% in the mild Cal/BD foam group and 7.1% in the mild vehicle group (P =.023). Conclusions: These important results establish treatment success for Cal/BD foam in mild psoriasis, a population in which efficacy is difficult to demonstrate since the treatment must completely clear visible disease to be considered effective.

Volume

83

Issue

6

First Page

AB198

This document is currently not available here.

Share

COinS